• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    New amorphous solid phases of sitagliptin are provided with coformmers derived from hydroxybenzoic, dihydroxybenzoic and trihydroxybenzoic acids; The new solid phases obtained have improved pharmaceutical properties, such as better solubility and higher dissolution rate than sitagliptin phosphate monohydrate and are also stable under environmental conditions. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2690866A1
    申请号:ES201731394
    申请日:2017-12-07
    公开日:2018-11-22
    发明作者:Jorge Guillermo Domínguez Chávez；Karina Mondragón Vásquez；Juan Pablo Senosiain Peláez
    申请人:Alparis SA De Cv；Alparis SA de CV；
    IPC主号:
    专利说明:

    5
    10
    fifteen
    twenty
    25
    NEW SOLID FORMS OF SITAGLIPTINA FIELD OF THE INVENTION
    The present invention relates to obtaining New Solid Phases (NFS), in particular to solid amorphous phases of sitagliptin as part of a stable sitagliptin-coformor binary system that exhibits greater solubility and dissolution rate than sitagliptin salt; wherein the coformers used are derivatives of n-hydroxybenzoic acids.
    BACKGROUND OF THE INVENTION
    Sitagliptin is marketed as a phosphate salt and is chemically known as phosphate monohydrate of (R) -4-oxo-4- [3- (trifluoromethyl) -5,6-dihydro [1,2,4] triazole [4, 3-a] pyrazin- 7 (8H) -yl] -1- (2,4,5-trifluorophenyl) butan-2-amine. This salt has the following structure:
    image 1
    Sitagliptin is a drug used for the treatment of Type 2 Diabetes Mellitus and belongs to the group of gliptins. Sitagliptin is a slightly hygroscopic and easily manipulated white crystalline solid; Its structure has a chiral center consisting of a primary amino group.
    Its mechanism of action is related to the inhibition of dipeptidylpetidase (DPP-4), which allows the increase in the incretin hormones GLP-1 and GIP that control the release of insulin and glucagon in the pancreas.
    5
    10
    fifteen
    twenty
    25
    30
    On the other hand, it has been described that the application of crystal engineering provides a viable alternative to improve the physicochemical properties of drugs without modifying their chemical structure. The physicochemical properties of active pharmaceutical ingredients and bulk materials can be modified, maintaining the intrinsic therapeutic activity of the molecule (Yadav A., et. Al. Co-Crystals: A Novel Approach to Modify Physicochemical Properties of Active Pharmaceutical Ingredients, 2009).
    The above is based on the ability of a molecule to exist in two or more solid forms, which differ in the spatial arrangement of atoms or molecules.
    As a result of the spatial arrangements of atoms or molecules, solids have different physical and chemical properties, which modify chemical stability, thermal stability, density, hardness, hygroscopic tendency, flow rate, absorption rate (bioavailability) or suspension behavior of the compound and therefore, in the final pharmaceutical product.
    In the prior art, various crystalline forms of sitagliptin salts have been described, as well as processes for obtaining them. Specifically, US 6,699,871 B2 provides a process for the preparation of sitagliptin base and its hydrochloric salt; while US 7,326,708 discloses a crystalline form of sitagliptin phosphate monohydrate and a process for its elaboration.
    EP 2318411 A2 is directed to crystalline salts of sitagliptin with a monobasic, dibasic or tribasic acid, while WO 2005/072530 discloses salts of sitagliptin and hydrates thereof, wherein the acid addition salt is selected from the group that It consists of hydrochloric acid, tartaric acid, benzenesulfonic acid, p-toluenesulfonic acid and 10-camphorsulfonic acid.
    WO 2009/085990 and WO 2010/092090 describe crystalline forms of sitagliptin added with coformers selected from sulfuric acid, hydrobromic acid, methanesulfonic acid, acetic acid, benzoic acid, oxalic acid, succinic acid, mandelic acid, fumaric acid, D-glucoronic acid , L-lactic acid, malonic acid, citric acid, crotonic acid, ascorbic acid, among others.
    5
    10
    fifteen
    twenty
    25
    30
    WO 2013/054364 A2 relates to solid forms of sitagliptin, particularly to acid addition salts anti-oxidants of sitagliptin, processes for its preparation and pharmaceutical compositions containing said salts.
    US 20140081026 A1 describes a process for the synthesis and industrial production of sitagliptin. On the other hand, US 20150051213 A1 provides sitagliptin salts with organic acids, polymorphic forms, processes for their preparation and pharmaceutical compositions thereof.
    An amorphous solid is one whose particles lack a long-range order. Amorphous solids are a way to increase the bioavailability of low solubility drugs by improving their dissolution rate and solubility (Guy Van Den Mooter, The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate, 2012 ).
    In amorphous solids, molecular energy is high and has a greater molecular mobility than in the crystalline state. These characteristics give the amorphous solids unique physicochemical properties such as, greater solubility and a higher dissolution rate in aqueous media (Yihong Qiu, et. Al. Developing Solid Oral Dosage Forms, 2009).
    As for solid amorphous phases, WO 2010/000469 discloses obtaining an amorphous of sitagliptin with citric acid. In WO 2012/131005, pharmaceutical compositions comprising amorphous sitagliptin are described, wherein the amorphous sitagliptin is prepared from a solution comprising sitagliptin and a crystallization inhibitor that is selected from cellulose derivatives, polyvinylpyrrolidone, derivatives of polyvinylpyrrolidone and / or mixtures thereof.
    US 20140350023 A1 discloses amorphous forms of sitagliptin obtained with maleic acid, fumaric acid, benzenesulfonic acid, methanesulfonic acid and succinic acid. WO 2015/114657 A2 provides amorphous forms of sitagliptin in the absence of coformers.
    5
    10
    fifteen
    twenty
    25
    30
    As mentioned above, there are reports of obtaining amorphous solids of sitagliptin; however, the coformers used in the present invention, as well as the advantages associated with their use, have not been disclosed, together with the fact that the methods of obtaining described in the state of the art are complex.
    Although amorphous solids possess interesting properties from a pharmaceutical point of view, as it is a greater solubility, they are not normally marketed due to their lower chemical stability, greater hygroscopicity and tendency to crystallize.
    Therefore, there is a need for New Solid Phases (NFS) of sitagliptin with improved physicochemical properties that are obtained by a simple method and that are also stable under environmental conditions.
    BRIEF DESCRIPTION OF THE INVENTION
    The present invention describes solid phases, obtained from a sitagliptin salt and a coformor derived from n-hydroxybenzoic acids. The n-hydroxybenzoic acids comprise hydroxybenzoic, dihydroxybenzoic and trihydroxybenzoic acids, specifically, coformers are selected from 2-hydroxybenzoic acid (2-HBA), 3-hydroxybenzoic acid (3-HBA), 4-hydroxybenzoic acid (4-HBA), 2, 3-Dihydroxybenzoic (2,3-DHBA), 2,4-dihydroxybenzoic (2,4-DHBA), 2-5-dihydroxybenzoic (2,5-DHBA), 2,6-dihydroxybenzoic (2,6-DHBA), 3,4-dihydroxybenzoic (3,4-DHBA), 3,5-dihydroxybenzoic (3,5-DHBA) and 3,4,5-trihydroxybenzoic (3,4,5-THBA). The solid phases obtained have different and improved physicochemical properties, such as solubility and dissolution rate compared to the sitagliptin salt.
    BRIEF DESCRIPTION OF THE FIGURES
    The following figures are included to illustrate certain aspects of the present invention, and should not be viewed as exclusive modalities.
    Figure 1 provides the powder X-ray diffraction spectra for: a) crystalline sitagliptin monohydrate monophosphate; b) amorphous sitagliptin monohydrate monophosphate; c) NFS sitagliptin-3-HBA; d) NFS sitagliptin-4-HBA; e) NFS sitagliptin-2,3-DHBA; f) NFS
    5
    10
    fifteen
    twenty
    25
    30
    sitagliptin-2,4-DHBA; g) NFS sitagliptin-2,5-DHBA; h) NFS sitagliptin-2,6-DHBA; i) NFS sitagliptin-3,5-DHBA; and j) NFS sitagliptin-3,4,5-THBA.
    Figure 2a shows Raman spectra of: a) NFS sitagliptin-3-HBA; b) Sitagliptin phosphate monohydrate; and c) 3-HBA.
    Figure 2b shows Raman spectra of: a) NFS sitagliptin-4-HBA; b) Sitagliptin phosphate monohydrate; and c) 4-HBA.
    Figure 2c represents Raman spectra of: a) NFS sitagliptin-2,3-DHBA; b) Sitagliptin phosphate monohydrate; and c) 2,3-DHBA.
    Figure 2d shows Raman spectra of: a) NFS sitagliptin-2,4-DHBA; b) Sitagliptin phosphate monohydrate; and c) 2,4-DHBA.
    Figure 2e provides Raman spectra of: a) NFS sitagliptin-2,5-DHBA; b) Sitagliptin phosphate monohydrate; and c) 2,5-DHBA.
    Figure 2f shows Raman spectra of: a) NFS sitagliptin-2,6-DHBA; b) Sitagliptin phosphate monohydrate; and c) 2,6-DHBA.
    Figure 2g represents Raman spectra of: a) NFS sitagliptin-3,4-DHBA; b) Sitagliptin phosphate monohydrate; and c) 3,4-DHBA.
    Figure 2h shows Raman spectra of: a) NFS sitagliptin-3,5-DHBA; b) Sitagliptin phosphate monohydrate; and c) 3,5-DHBA.
    Figure 2i shows Raman spectra of: a) NFS sitagliptin-3,4,5-THBA; b) Sitagliptin phosphate monohydrate; and c) 3,4,5-THBA.
    Figure 3a provides IR spectra of: a) crystalline sitagliptin phosphate monohydrate; b) amorphous sitagliptin monohydrate phosphate; c) 3-HBA; and d) NFS sitagliptin-3-HBA.
    5
    10
    fifteen
    twenty
    25
    30
    Figure 3b represents IR spectra of: a) crystalline sitagliptin phosphate monohydrate; b) amorphous sitagliptin monohydrate phosphate; c) 4-HBA; and d) NFS sitagliptin-4-HBA.
    Figure 3c shows IR spectra of: a) crystalline sitagliptin phosphate monohydrate;
    b) amorphous sitagliptin monohydrate phosphate; c) 2,3-DHBA; and d) NFS sitagliptin-2,3-DHBA.
    Figure 3d shows IR spectra of: a) crystalline sitagliptin phosphate monohydrate; b) amorphous sitagliptin monohydrate phosphate; c) 2,4-DHBA; and d) NFS sitagliptin-2,4-DHBA.
    Figure 3e shows IR spectra of; a) crystalline sitagliptin monohydrate phosphate; b) amorphous sitagliptin monohydrate phosphate; c) 2,5-DHBA; and d) NFS sitagliptin-2,5-DHBA.
    Figure 3f provides IR spectra of: a) crystalline sitagliptin phosphate monohydrate; b) amorphous sitagliptin monohydrate phosphate; c) 2,6-DHBA; and d) NFS sitagliptin-2,6-DHBA.
    Figure 3g represents IR spectra of: a) crystalline sitagliptin phosphate monohydrate; b) amorphous sitagliptin monohydrate phosphate; c) 3,4-DHBA; and d) NFS sitagliptin-3,4-DHBA.
    Figure 3h shows IR spectra of: a) crystalline sitagliptin phosphate monohydrate; b) amorphous sitagliptin monohydrate phosphate; c) 3,5-DHBA; and d) NFS sitagliptin-3,5-DHBA.
    Figure 3i shows IR spectra of; a) crystalline sitagliptin monohydrate phosphate; b) amorphous sitagliptin monohydrate phosphate; c) 3,4,5-THBA; and d) NFS sitagliptin-3,4,5-THBA.
    Figure 4 represents the results of dissolution rate studies of: a) NFS sitagliptin-2,5-DHBA (▼); b) NFS sitagliptin-3,5-DHBA (•); c) NFS sitagliptin-2,4-DHBA (▲); d) NFS sitagliptin-3,4-DHBA (^); e) NFS sitagliptin-2,3-DHBA (♦); f) Crystalline sitagliptin monohydrate phosphate (•); g) NFS sitagliptin-4-HBA (■); and h) NFS sitagliptin-3,4,5-THBA (★).
    An X-ray diffraction spectrum of the NFS sitagliptin-3,4,5-THBA in different conditions is displayed in Figure 5a: 50 ° C / dry, 40 ° C / dry and 40 ° C / 75% relative humidity ( HR) for one month.
    5
    10
    fifteen
    twenty
    25
    30
    Figure 5b provides an X-ray diffraction spectrum of the NFS sitagliptin-3,5-DHBA under different conditions: 50 ° C / dry, 40 ° C / dry and 40 ° C / 75% relative humidity (RH) for a month.
    Figure 5c represents an X-ray diffraction spectrum of the NFS sitagliptin-2,5-DHBA under different conditions: 50 ° C / dry, 40 ° C / dry and 40 ° C / 75% relative humidity (RH) for a month.
    Figure 5d shows an X-ray diffraction spectrum of the NFS sitagliptin-2,3-DHBA under different conditions: 50 ° C / dry, 40 ° C / dry and 40 ° C / 75% relative humidity (RH) for a month.
    X-ray diffractograms of NFS powders are observed in Figure 6: a) sitagliptin-2,3-DHBA; b) sitagliptin-2,5-DHBA; c) sitagliptin-3,5-DHBA; and d) sitagliptin-3,4,5-THBA, after one year of storage.
    DETAILED DESCRIPTION OF THE INVENTION
    The present invention provides NFS of sitagliptin with improved physicochemical properties, such as greater solubility, dissolution rate, stability and ease of flow.
    As used in the present invention, the term "New Solid Phase" (NFS) refers to a solid phase consisting of a mixture of sitagliptin and a coform, which interacts with sitagliptin through weak bonds.
    The NFS of the present invention are formed from a sitagliptin salt and a coform, resulting in a binary sitagliptin-coform system. The NFS obtained are constituted by an aggregate in which the components of the drug and the coformator molecule do not interact covalently, that is, they have weak interactions, such as hydrogen bonds, ionic pairs or Van der Waals type interactions.
    As used in the present invention, the term "coformator" refers to a compound that, in combination with the sitagliptin salt, allows the creation of an NFS. As described in the present invention, the coformer only exhibits weak interactions with the sitagliptin.
    5
    10
    fifteen
    twenty
    25
    30
    In one embodiment, the NFS are formed from the crystalline form sitagliptin phosphate salt monohydrate.
    The coformers used in the present invention are derivatives of n-hydroxybenzoic acids. In one embodiment, n-hydroxybenzoic acids comprise hydroxybenzoic, dihydroxybenzoic and trihydroxybenzoic acids; preferably 2- hydroxybenzoic acid (2-HBA), 3-hydroxybenzoic acid (3-HBA), 4-hydroxybenzoic acid (4-HBA), 2,3-
    dihydroxybenzoic (2,3-DHBA), 2,4-dihydroxybenzoic (2,4-DHBA), 2-5-dihydroxybenzoic (2,5-DHBA), 2,6-dihydroxybenzoic (2,6-DHBA), 3, 4-dihydroxybenzoic acid (3,4-DHBA), 3,5-
    dihydroxybenzoic acid (3,5-DHBA) and 3,4,5-trihydroxybenzoic acid (3,4,5-THBA). The coformers provide the NFS with stability in environmental conditions.
    As described in the present invention, the NFS have an improved dissolution rate, with respect to the sitagliptin salt.
    In another aspect a process for the elaboration of the NFS is provided, which includes the steps of:
    a) Provide a mixture comprising sitagliptin and an n-hydroxybenzoic acid derivative
    b) Dissolve the mixture comprising sitagliptin and a derivative of n-hydroxybenzoic acid in methanol or ethanol
    c) Place the mixture on a rotary evaporator
    d) Heat in a bath at 70-85 ° C at a reduced pressure.
    As described in the present invention, the mixture of sitagliptin and coformor corresponds to a stoichiometric mixture with a 1: 1 ratio of sitagliptin: coformor.
    5
    10
    fifteen
    twenty
    25
    30
    The following examples are intended to illustrate and demonstrate some embodiments of the invention. The exemplified embodiments should not be considered as limiting the present invention. As one skilled in the art will be able to recognize, modifications and variations can be made to the modalities described herein without altering the essence of the invention.
    1. Characterization of the NFS
    The NFS obtained are characterized by powder X-ray diffraction, Raman spectroscopy and Infrared (IR) spectroscopy.
    a) Characterization of the NFS by X-ray powder diffraction.
    The X-ray diffraction of powders determines the degree of molecular order in a solid, therefore, it allows to distinguish the presence of crystals or amorphous from powder samples. In the powder diffractograms shown in Figure 1, diffuse halos are observed without diffraction peaks with respect to the crystalline sitagliptin salt, demonstrating a loss of crystallinity and, therefore, the presence of non-crystalline NFS.
    Figure 1 provides the powder X-ray diffraction spectra for: a) crystalline sitagliptin monohydrate monophosphate; b) amorphous sitagliptin monohydrate monophosphate; c) NFS sitagliptin-3-HBA; d) NFS sitagliptin-4-HBA; e) NFS sitagliptin-2,3-DHBA; f) NFS sitagliptin-2,4-DHBA; g) NFS sitagliptin-2,5-DHBA; h) NFS sitagliptin-2,6-DHBA; i) NFS sitagliptin-3,5-DHBA; and j) NFS sitagliptin-3,4,5-THBA.
    b) Characterization of NFS by Raman spectroscopy
    Raman spectroscopy is sensitive to the formation of weak intermolecular forces. Figures 2a-2i show comparisons of Raman spectra of the sitagliptin salt, coformers and NFS. In these figures, the spectrum of
    5
    10
    fifteen
    twenty
    25
    30
    the NFS; with subparagraph b) the spectrum of sitagliptin phosphate monohydrate is represented; and subsection c) corresponds to the spectrum of the coformer.
    From these spectra it can be noted that displacements of the Raman bands of the NFS are observed, indicating the establishment of intermolecular interactions between the drug and the coformer.
    c) Characterization of NFS by Infrared Spectroscopy (IR)
    One of the main applications of IR Spectroscopy is the characterization of substances by identifying specific functional groups, especially organic molecules. In Figures 3a-3i, comparisons of the IR spectra of the crystalline sitagliptin salt, amorphous sitagliptin salt, coformers and NFS are visualized. In these figures, the spectrum of sitagliptin phosphate monohydrate is represented by part a); subsection b) represents the amorphous sitagliptin monohydrate phosphate spectrum; subsection c) corresponds to the spectrum of the coformer; and subsection d) corresponds to the spectrum of the NFS.
    Specifically, a loss of definition of the bands with respect to the crystalline sitagliptin salt is observed, as it occurs in the new amorphous phases.
    2. Solubility studies
    The solubility studies are carried out in physiologically relevant media such as hydrochloric acid at pH 1.2, acetate at pH 4.5, phosphate at pH 6.8 and water. A supersaturated solution of the phase is made and left under stirring at 37 ° C for 72 h, after the time the mixture is filtered and the filtered liquid is analyzed by UV-Vis spectroscopy; Finally, the concentration of the solution is calculated to obtain the amount (mg) dissolved.
    Due to the high solubility of the NFS, supersaturation of the solution is not achieved. In one embodiment of the invention 250 mg of the NFS were added at 200 ^ L of the solvent, however, there is only formation of a gel which solidifies.
    5
    10
    fifteen
    twenty
    25
    30
    The dissolution profile of the sitagliptin salt compared to the NFS is shown in Figure 4. The dissolution speed tests were performed in water, using Wood's equipment with 150 milligram tablets, the study was done at 37 ° C at 50 rpm.
    The NFS have an increased solubility with respect to the salt of sitagliptin. In one embodiment of the present invention, an NFS is obtained with an increase in solubility of up to 400% with respect to the sitagliptin salt and with a dissolution percentage of 92.51% when the coformor is 2,5-DHBA.
    4. Stability studies
    Stability studies are carried out keeping the NFS at room temperature for a certain time. Once the time has elapsed, a visual evaluation of the samples is carried out, and an analysis by X-ray diffraction in order to compare the spectra obtained at the beginning of the test and detect a possible change in the NFS.
    a) Visual evaluation
    In one embodiment of the invention, after one month exposed to the conditions described above, the NFS have a dry foam appearance when the coform is selected from 3- HBA, 4-HBA, 2,3-DHBA, 2,4- DHBA, 2,5-DHBA, 3,5-DHBA and 3,4,5-THBA.
    b) X-ray diffraction
    In Figure 5b it can be seen that the NFS obtained with the 3,5-DHBA coformor has slight diffraction peaks corresponding to the crystallization of the drug at conditions of 40 ° C and 75% RH. When the coformer is 2,3-DHBA, 2,5-DHBA, and 3,4,5-THBA (Figures 5a, 5c, 5d), the NFS are stable under conditions of 50 ° C dry, 40 ° C dry and 40 ° C at 75% RH for one month.
    In X-ray diffractograms of NFS powders with one year in storage at room temperature (Figure 6), there is no presence of diffraction peaks indicating the presence of any
    crystallized component In this sense, the NFS are stable for a year when the coformer is 2,3-DHBA, 2,5-DHBA, 3,5-DHBA and 3,4,5-THBA.
    权利要求:
    Claims (6)
    [1]
    5
    10
    fifteen
    twenty
    25
    30
    1. A solid amorphous phase of sitagliptin and a coform, characterized in that the coform is a derivative of n-hydroxybenzoic acid.
    [2]
    2. The solid phase according to claim 1, characterized in that the coform is a derivative of hydroxybenzoic, dihydroxybenzoic and trihydroxybenzoic acids.
    [3]
    3. The solid phase according to claim 1, characterized in that the coform is selected from the group of 2-hydroxybenzoic, 3-hydroxybenzoic, 4-hydroxybenzoic, 2,3-dihydroxybenzoic, 2,4-dihydroxybenzoic, 2-5- dihydroxybenzoic, 2,6-dihydroxybenzoic, 3,4-dihydroxybenzoic, 3,5-dihydroxybenzoic and 3,4,5-trihydroxybenzoic.
    [4]
    4. The solid phase according to claim 1, characterized in that it is stable under environmental conditions.
    [5]
    5. The solid phase according to claim 1, characterized in that it has a solubility and dissolution rate greater than sitagliptin phosphate monohydrate.
    [6]
    6. A process for obtaining solid phases of sitagliptin according to any of claims 1-4, characterized in that it comprises the steps of:
    a) it is based on a combination comprising sitagliptin and a derivative of n-hydroxybenzoic acid
    b) dissolve the mixture comprising sitagliptin and a derivative of hydroxybenzoic acid in methanol or ethanol
    c) place the mixture on a rotary evaporator
    d) heat in a bath at 70-85 ° C at a reduced pressure.
    类似技术:
    公开号 | 公开日 | 专利标题
    US8389512B2|2013-03-05|In vivo studies of crystalline forms of meloxicam
    ES2552386T3|2015-11-27|Propane-1-sulfonic acid {3- [5- | -1H-pyrrole [2,3-b] pyridin-3-carbonyl] -2,4-difluoro-phenyl} -amide compositions and uses thereof
    ES2676319T3|2018-07-18|Pteroestilbeno co-crystals
    ES2819305T3|2021-04-15|Combination of a naloxol-peg conjugate and an opioid agonist
    BR112020014487A2|2020-12-01|pharmaceutical compositions for the treatment of cystic fibrosis
    CA2970799A1|2016-06-30|L-tartrate salt of pridopidine
    AU2013333953A1|2015-04-30|Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
    Lin et al.2016|Mechanism study on stability enhancement of adefovir dipivoxil by cocrystallization: degradation kinetics and structure-stability correlation
    TW201120034A|2011-06-16|Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
    JP4566128B2|2010-10-20|Method for producing crystalline polymorph of irinotecan hydrochloride
    BRPI0719236A2|2014-07-08|FENILALKYL CARBAMATE COMPOSITIONS
    US20200376004A1|2020-12-03|Amorphous onapristone compositions and methods of making the same
    Aitipamula et al.2018|Evaluating suspension formulations of theophylline cocrystals with artificial sweeteners
    WO2007080362A1|2007-07-19|Pharmaceutically acceptable co-crystalline forms of sildenafil
    ES2690866B2|2019-10-02|NEW SOLID FORMS OF SITAGLIPTINA
    US20210087176A1|2021-03-25|Polymorphs and solid forms of a pyrimidinylamino-pyrazole compound, and methods of production
    CN105358557A|2016-02-24|Polymorphs and salts of a compound
    ES2326493T3|2009-10-13|MALEATE OF 3- | METHYL- |) PHENOL AND ITS CRYSTAL FORMS
    JP2013528213A|2013-07-08|Ezathiostat tablet formulation
    JP2019509314A|2019-04-04|Salt form of DPPIV inhibitor and method for producing the same
    TW200900393A|2009-01-01|Salts of picotamide
    RU2721335C1|2020-05-19|Co-crystalline form of 1-[|-1,2,4-thiadiazol-3-yl]-propan-2-ol
    WO2018130226A1|2018-07-19|New crystal form of riociguat, preparation method and use thereof
    TWI754605B|2022-02-11|Salts of indole derivatives and their crystals
    WO2020233226A1|2020-11-26|B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application
    同族专利:
    公开号 | 公开日
    US20180170937A1|2018-06-21|
    US10301316B2|2019-05-28|
    MX2016016260A|2018-06-07|
    CA2988285A1|2018-06-08|
    ES2690866B2|2019-10-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    WO2012147092A2|2011-03-03|2012-11-01|Cadila Healthcare Limited|Novel salts of dpp-iv inhibitor|
    WO2013001457A1|2011-06-30|2013-01-03|Ranbaxy Laboratories Limited|Novel salts of sitagliptin|
    WO2016046679A1|2014-09-28|2016-03-31|Mohan M Alapati|Compositions and methods for the treatment of diabetes and pre-diabetes|
    AR036114A1|2001-07-06|2004-08-11|Merck & Co Inc|TETRAHYDROIMIDAZOL [1,2-A] PIRAZINS AND TETRAHYDROTRIAZOL [4,3-A] PIRAZINS AS INHIBITORS OF DIPEPTIDIL PEPTIDASE USEFUL FOR THE TREATMENT OR PREVENTION OF DIABETES|
    JO2625B1|2003-06-24|2011-11-01|ميرك شارب اند دوم كوربوريشن|Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor|
    EP1708571A4|2004-01-16|2009-07-08|Merck & Co Inc|Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor|
    US8309724B2|2007-12-20|2012-11-13|Dr. Reddy's Laboratories Limited|Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof|
    EP2586782B2|2008-07-03|2017-10-04|ratiopharm GmbH|Crystalline salts of sitagliptin|
    EP2218721A1|2009-02-11|2010-08-18|LEK Pharmaceuticals d.d.|Novel salts of sitagliptin|
    WO2012131005A1|2011-03-29|2012-10-04|Krka, Tovarna Zdravil, D.D., Novo Mesto|Pharmaceutical composition of sitagliptin|
    ITMI20110765A1|2011-05-05|2012-11-06|Chemo Iberica Sa|PROCESS FOR SITAGLIPTINA PRODUCTION|
    CN103649090A|2011-10-14|2014-03-19|劳乐斯实验室私营有限公司|Novel salts of sitagliptin, process for the preparation and pharmaceutical composition thereof|
    EP2788352A1|2011-12-08|2014-10-15|Ranbaxy Laboratories Limited|Amorphous form of sitagliptin salts|
    IN2014MU00212A|2014-01-21|2015-08-28|Cadila Healthcare Ltd|
    法律状态:
    2018-11-22| BA2A| Patent application published|Ref document number: 2690866 Country of ref document: ES Kind code of ref document: A1 Effective date: 20181122 |
    2019-10-02| FG2A| Definitive protection|Ref document number: 2690866 Country of ref document: ES Kind code of ref document: B2 Effective date: 20191002 |
    优先权:
    申请号 | 申请日 | 专利标题
    MX/A/2016/016260|2016-12-08|
    MX2016016260A|MX2016016260A|2016-12-08|2016-12-08|New solid forms of sitagliptin.|
    [返回顶部]